Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007342
Chunk: 24

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 24
---
 and do not anticipate paying any cash dividends on
our Ordinary Shares or the Depositary Shares in the foreseeable future. We intend to retain all available funds and any future earnings
to fund the development and expansion of our business. As a result, investors in the Ordinary Shares and Depositary Shares will benefit
in the foreseeable future only if the Ordinary Shares and Depositary Shares appreciate in value.

Any
determination to pay dividends in the future would be at the discretion of our Board of Directors and will depend upon our results of
operations, cash requirements, financial condition, contractual restrictions, and any future debt agreements and is subject to compliance
with applicable laws, including the United Kingdom Companies Act of 2006, or the Companies Act, which requires English companies to have
profits available for distribution equal to or greater than the amount of the proposed dividend.

| 19 |

<div align='center'>CAPITALIZATION</div>

The following table sets forth our capitalization
as of December 31, 2024. The information in this table should be read in conjunction with our “Management Discussion and Analysis
of Financial Condition and Results of Operations” and our consolidated financial statements and notes thereto and other financial
information incorporated by reference into this prospectus.

| (£ in thousands)          |     | As of December 31, 2024 |       |
|:--------------------------|:----|:------------------------|------:|
| Cash and cash equivalents |     |                         | 1,669 |
| Long-term debt            |     |                         |   118 |
| Total equity              |     |                         | 8,322 |
| Total capitalization      |     |                         | 8,440 |

The table above does not include, as of December
31, 2024:

| · | 328,823,388 Ordinary Shares issuable upon the exercise of stock options outstanding under our equity incentive plans at a weighted-average 
 exercise price of £0.005 per share;                                                                                                        |

| · | 99 Ordinary Shares issuable upon the exercise of stock options in connection with the acquisition of Dara (as defined below) at a 
 weighted average exercise price of $877.13 per share; and                                                                         |

| · | warrants, including pre-funded warrants, exercisable for 770,026 Depositary                                               
 Shares (representing 7,700,260,000 Ordinary Shares), at a weighted average exercise price of $38.42 per Depositary Share. |

| 20 |

<div align